27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Vitamin D has gained interest as a potentially modifiable risk factor for dementia because of its putative neuroprotective effects. 4 key findings →
Design: longitudinal study Participants: 6,220 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We investigated the associations between retinopathy and dementia and its subtypes Alzheimer disease (AD) and vascular dementia both cross-sectionally and prospectively in the Rotterdam Study, a large population-based cohort study. 4 key findings →
Design: cohort study Participants: 195 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Cerebral vasoreactivity (CVR) is a key factor in maintenance of continuous cerebral perfusion and a marker of (micro)vascular damage. 4 key findings →
Design: longitudinal study Participants: 1,629 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Stroke is associated with a higher LBD risk. 5 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Over 7,430,253 person-years of follow-up, 11,345 dementia cases occurred (10,863 AD and 2,159 VaD). 5 key findings →
Design: cohort study Participants: 296,001 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In this observational study, zinc deficiency was associated with increased 1-year mortality and infection-related complications in patients with dementia, with evidence of a dose–response relationship. 5 key findings →
Design: cohort study Participants: 1,241 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In both the mortality and readmission cohorts we found significant associations with each pollutant. 5 key findings →
Design: retrospective cohort Participants: 118 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In the UK Biobank cohort (N = 166,916), MIND diet demonstrated the broadest neuroprotective effects. 5 key findings →
Design: prospective cohort Participants: 166,916 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Anemia among older adults aged ≥ 60 years is a well-described risk factor that increases the risk of falls, cardiovascular diseases, and mortality. 4 key findings →
Design: longitudinal study Participants: 3,252 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our findings suggest that the informant report is particularly relevant in patients with MCI where it strongly relates to higher amyloid-PET, indicative of impairment due to AD. 2 key findings →
Design: cross-sectional Participants: 25 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Mean IGF-1 levels were 144 ± 60 μg/L in generation 1 and 114 ± 37 μg/L in generation 2. 3 key findings →
Participants: 789 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We systematically compared structural imaging patterns of advanced brain aging (ABA) in the general-population, herein defined as significant deviation from typical BA to those found in Alzheimer disease (AD). 5 key findings →
Participants: 2,705 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The data do not support an association between serum total cholesterol or high density lipoprotein in late life and subsequent risk of dementia or Alzheimer disease (AD). 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Obesity at midlife is associated with an increased risk of dementia and AD later in life. 3 key findings →
Participants: 1,449 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Nearly half of all adults older than 60 years of age report sleep disturbance, as characterised either by reports of insomnia complaints with daytime consequences, dissatisfaction with sleep quality or quantity, or the diagnosis of insomnia disorder. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In recent years, accumulating evidence has suggested that vascular risk factors contribute to Alzheimer disease (AD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The late-life dementia risk index accurately stratified older adults into those with low, moderate, and high risk of developing dementia. 2 key findings →
Participants: 480 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Central auditory speech-processing deficits may be an early manifestation of probable Alzheimer's disease and may precede the onset of dementia diagnosis by many years. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Over an average follow-up of 4 y, dementia developed in 112 subjects, including 70 who received a diagnosis of AD. 3 key findings →
Design: cross-sectional Participants: 816 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Depressive symptoms appeared to be early manifestations, rather than predictors, of Alzheimer disease in this community sample. 3 key findings →
Participants: 1,366 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Despite lower dementia prevalence, Black participants with dementia had more dementia risk factors, as well as greater cognitive impairment and neuropsychiatric symptom severity than White participants. 1 key finding →
Participants: 5,700 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Sensory impairments were common: 28% had visual impairment, 35% had hearing loss, 22% had poor smell, 12% had touch insensitivity; 26% had more than two impairments, and 5.6% had more than three sensory impairments. 2 key findings →
Participants: 1,810 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Study objectives To examine associations between positive airway pressure (PAP) therapy, adherence and incident diagnoses of Alzheimer's disease (AD), mild cognitive impairment (MCI), and dementia not otherwise specified (DNOS) in older adults. 5 key findings →
Participants: 1,057 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Poisson regression was used to model dementia incidence as a function of age, sex, educational level, race, and birth cohort, with profile likelihood used to identify the timing of significant increases or decreases in incidence. 3 key findings →
Participants: 1,348 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
When compared with the Low MedDiet group, the High MedDiet group was associated with better L&M performance and larger dentate gyri. 5 key findings →
Design: cross-sectional Participants: 82 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
10 of the 1,130 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →